{"groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.\n\nParticipants who experienced progressive disease or did not respond to therapy within 12 months may have received crossover treatment with zanubrutinib plus obinutuzumab at the investigator's discretion.","id":"FG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"FG001","title":"Zanubrutinib + Obinutuzumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"51"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"55"}],"type":"Study Closed by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"30"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Remained on Study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"145"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"143"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"0"}],"type":"Crossover to Combination Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"145"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"After enrollment, participants were randomized 2:1 to zanubrutinib plus obinutuzumab or obinutuzumab alone, stratified by prior therapy, rituximab-refractory status, and region. Treatment began within 5 days, in 28-day cycles. At investigator discretion, those on obinutuzumab monotherapy could cross over to zanubrutinib plus obinutuzumab if progressive disease or non-response was confirmed by independent central review.","recruitmentDetails":"Participants were enrolled in multiple study centers in Australia, Europe, Asia, and North America."}